Have only followed IXC after the IPO and only just noticed IXC again over the last week, going from 60 cents to now less than 20 cents. Has this orphan drug designation been devalued because of the most recent Phase 3 trial update????
With cash backing at around 30 cents and outflows not looking too significant and with R&D refund or so from what I've read, why do post in here sound so negative. Biotech companies are generally extremely risky so the falls are quite dramatic.
Ann: Invex Granted European Orphan Drug Designation for TBI, page-74
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.960M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 6.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.8¢ | 10000 | 1 |
View Market Depth
| Last trade - 16.12pm 12/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable